Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis

Lisa M Lundquist1, Sabrina W Cole2, Jill M Augustine11Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, 2Wingate University School of Pharmacy, Wingate, NC, USAAbstract: Rheumatoid arthritis is a chronic, progressive, autoimmune disease that leads to significant disability and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Augustine JM, Cole SW, Lundquist LM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Diseases of the musculoskeletal system
RC925-935
Acceso en línea:https://doaj.org/article/69bc940bd45344239221e1b2b4a770bc
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:69bc940bd45344239221e1b2b4a770bc
record_format dspace
spelling oai:doaj.org-article:69bc940bd45344239221e1b2b4a770bc2021-12-02T02:26:47ZCritical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis1179-156Xhttps://doaj.org/article/69bc940bd45344239221e1b2b4a770bc2012-02-01T00:00:00Zhttp://www.dovepress.com/critical-appraisal-of-efficacy-and-safety-of-abatacept-in-the-treatmen-a9253https://doaj.org/toc/1179-156XLisa M Lundquist1, Sabrina W Cole2, Jill M Augustine11Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, 2Wingate University School of Pharmacy, Wingate, NC, USAAbstract: Rheumatoid arthritis is a chronic, progressive, autoimmune disease that leads to significant disability and premature mortality. Various treatment options are available, but the foundation of treatment includes nonbiologic and biologic disease-modifying antirheumatic drugs. The incidence of patients with rheumatoid arthritis refractory to first-line agents is estimated to be at least 20%. Abatacept, a T cell costimulation modulator, is the first agent to interfere with full T cell activation by competing with CD28 for binding of CD80 and CD86, which results in decreased secretion of proinflammatory cytokines and autoantibody production. Current American College of Rheumatology treatment guidelines recommend abatacept for patients with at least moderate disease activity and a poor prognosis demonstrating an inadequate response to other agents. Several key Phase III trials have been conducted to evaluate the efficacy and safety of abatacept in patients with an inadequate response to methotrexate or anti-tumor necrosis factor alpha therapy. Response rates in all trials showed statistically significant improvements compared with placebo according to American College of Rheumatology criteria for disease improvement. The most common adverse event report in patients receiving abatacept was infection; however, the frequency of adverse events was similar to placebo. Abatacept is a safe and effective rheumatoid arthritis treatment for patients with an inadequate response to methotrexate or anti-tumor necrosis factor alpha therapy.Keywords: abatacept, rheumatoid arthritis, treatment refractory, biologic, disease-modifying antirheumatic drugsAugustine JMCole SWLundquist LMDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2012, Iss default, Pp 9-19 (2012)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the musculoskeletal system
RC925-935
spellingShingle Diseases of the musculoskeletal system
RC925-935
Augustine JM
Cole SW
Lundquist LM
Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
description Lisa M Lundquist1, Sabrina W Cole2, Jill M Augustine11Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, 2Wingate University School of Pharmacy, Wingate, NC, USAAbstract: Rheumatoid arthritis is a chronic, progressive, autoimmune disease that leads to significant disability and premature mortality. Various treatment options are available, but the foundation of treatment includes nonbiologic and biologic disease-modifying antirheumatic drugs. The incidence of patients with rheumatoid arthritis refractory to first-line agents is estimated to be at least 20%. Abatacept, a T cell costimulation modulator, is the first agent to interfere with full T cell activation by competing with CD28 for binding of CD80 and CD86, which results in decreased secretion of proinflammatory cytokines and autoantibody production. Current American College of Rheumatology treatment guidelines recommend abatacept for patients with at least moderate disease activity and a poor prognosis demonstrating an inadequate response to other agents. Several key Phase III trials have been conducted to evaluate the efficacy and safety of abatacept in patients with an inadequate response to methotrexate or anti-tumor necrosis factor alpha therapy. Response rates in all trials showed statistically significant improvements compared with placebo according to American College of Rheumatology criteria for disease improvement. The most common adverse event report in patients receiving abatacept was infection; however, the frequency of adverse events was similar to placebo. Abatacept is a safe and effective rheumatoid arthritis treatment for patients with an inadequate response to methotrexate or anti-tumor necrosis factor alpha therapy.Keywords: abatacept, rheumatoid arthritis, treatment refractory, biologic, disease-modifying antirheumatic drugs
format article
author Augustine JM
Cole SW
Lundquist LM
author_facet Augustine JM
Cole SW
Lundquist LM
author_sort Augustine JM
title Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
title_short Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
title_full Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
title_fullStr Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
title_full_unstemmed Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
title_sort critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/69bc940bd45344239221e1b2b4a770bc
work_keys_str_mv AT augustinejm criticalappraisalofefficacyandsafetyofabataceptinthetreatmentofrefractoryrheumatoidarthritis
AT colesw criticalappraisalofefficacyandsafetyofabataceptinthetreatmentofrefractoryrheumatoidarthritis
AT lundquistlm criticalappraisalofefficacyandsafetyofabataceptinthetreatmentofrefractoryrheumatoidarthritis
_version_ 1718402473991864320

Ejemplares similares